Generate Biomedicines, Inc. (GENB)
16.39
+0.05
(+0.31%)
USD |
NASDAQ |
Sep 04, 16:00
16.37
-0.02
(-0.12%)
Pre-Market: 20:00
Generate Biomedicines Research and Development Expense (Quarterly) : 61.12M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.12M |
| March 31, 2026 | 54.56M |
| Date | Value |
|---|---|
| June 30, 2025 | 56.45M |
| March 31, 2025 | 43.43M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Twist Bioscience Corp. | 18.02M |
| Intellia Therapeutics, Inc. | 80.50M |
| Prime Medicine, Inc. | 33.40M |
| Moderna, Inc. | 588.00M |
| Beam Therapeutics, Inc. | 95.10M |